pro2cool
Phase 3- Indications
- Concussion, Mild traumatic brain injury
Company intelligence / Profile preview
TecTraum has developed pro2cool®, a novel, noninvasive hypothermic therapy device for the treatment of concussion. The system provides localized cooling to the head and neck to lower blood temperature before it enters the brain, aiming to reduce severity and duration of concussion symptoms. A large multisite pivotal clinical trial in adolescents was completed in April 2022, showing significant improvements in clinical outcomes. The company is preparing data for FDA submission with plans for commercial launch pending regulatory clearance[1][3][6].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TecTraum.